Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.36 |
| ▸ | HTR2B | P41595 | 11/20 | 0.36 |
| ▸ | HTR2A | P28223 | 10/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18322272 | 0.98 | HTR2C (0.36) | HTR2CHTR2BHTR2ANOS3NOS1 | |
| SCHEMBL1583081 | 0.92 | NOS3 (0.39) | HTR2CHTR2BHTR2ANOS3NOS1 | |
| SCHEMBL1161615 | 0.92 | NOS3 (0.39) | HTR2CHTR2BHTR2ANOS3NOS1 | |
| SCHEMBL1583139 | 0.91 | ADORA2A (0.33) | HTR2CHTR2BHTR2A | |
| SCHEMBL1583608 | 0.91 | ADORA2A (0.33) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL1583544 | 0.90 | NOS3 (0.38) | HTR2CHTR2BHTR2ANOS3NOS1 | |
| Bromide SCHEMBL28435023 | 0.90 | NOS3 (0.38) | HTR2CHTR2BHTR2ANOS3NOS1 | |
| Hydrochloric Acid SCHEMBL1583243 | 0.90 | NOS3 (0.38) | HTR2CHTR2BHTR2ANOS3NOS1 | |
| SCHEMBL1583741 | 0.90 | POLB (0.39) | HTR2CHTR2BHTR2ANOS3NOS1 | |
| SCHEMBL1583135 | 0.90 | POLB (0.39) | HTR2CHTR2BHTR2ANOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | claimed |
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-20250388553-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | INCYTE CORP (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250381185-A1 | CDK4/PARP1 DUAL-TARGET INHIBITOR AND USE THEREOF | YANBIAN UNIVERSITY (CN) | 2025-12-18 | — | — | US | disclosed |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12421197-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2025-09-23 | — | — | US | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025092827-A1 | EPOXY COMPOUND AND USE THEREOF | 上海汇伦医药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-2430024-A1 | [1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | AstraZeneca AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | HTR2C 3758/4885HTR2B 3913/4885HTR2A 3665/4885 |
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | BCL6, BCL6B, BCL3 | HTR2C 1198/4885HTR2B 2804/4885HTR2A 2346/4885 |
| US-20250381185-A1 | CDK4/PARP1 DUAL-TARGET INHIBITOR AND USE THEREOF | CDK4, PARP11, PARP1 | HTR2C 4117/4885HTR2B 2214/4885HTR2A 3718/4885 |
| US-12421197-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | PIK3R5, PIK3CD, PIK3CG | HTR2C 3632/4885HTR2B 3257/4885HTR2A 2422/4885 |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | AR, NR5A1, KLK3 | HTR2C 871/4885HTR2B 1125/4885HTR2A 1479/4885 |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | HTR2C 3716/4885HTR2B 3830/4885HTR2A 4143/4885 |
| US-20250388553-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3C2B | HTR2C 1888/4885HTR2B 2657/4885HTR2A 1839/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | HTR2C 683/4885HTR2B 1389/4885HTR2A 1643/4885 |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GABRA5, SLC6A11, GABRA1 | HTR2C 309/4885HTR2B 388/4885HTR2A 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.